Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from VYNE Therapeutics ( (VYNE) ) is now available.
On August 11 and 13, 2025, Christine Borowski and Anthony Bruno resigned from VYNE Therapeutics‘ board, with no disputes involved. VYNE reported its second quarter 2025 financial results, highlighting a promising efficacy signal from its VYN202 program in a Phase 1b trial for plaque psoriasis. Despite a clinical hold due to testicular toxicity in dogs, the FDA lifted the hold for female subjects, and VYNE plans further studies. The company also reported mixed results from its Phase 2b trial of repibresib gel for vitiligo, leading to the trial’s termination. Financially, VYNE reduced costs, extending its cash runway into 2027, and reported a decreased net loss compared to the previous year.
The most recent analyst rating on (VYNE) stock is a Buy with a $5.75 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Underperform.
VYNE Therapeutics faces significant challenges, with financial instability, negative technical indicators, and a recent setback in its clinical trials. These factors contribute to a low stock score, underscoring the risks associated with investing in VYNE at this time.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need. The company leverages its proprietary BET inhibitors, part of the InhiBET™ platform, to overcome limitations of early generation BET inhibitors through alternative administration routes and enhanced selectivity.
Average Trading Volume: 1,808,606
Technical Sentiment Signal: Sell
Current Market Cap: $5.79M
See more insights into VYNE stock on TipRanks’ Stock Analysis page.